Teva wins reversal of US jury's US$235 million GSK drug patent verdict


A federal judge on Wednesday overturned a U.S. jury's verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than US$235 million for infringing a patent covering its blood pressure drug Coreg. REUTERS: A federal judge on Wednesday overturned a U.S. jury's verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than US$235 million for infringing a patent covering its blood pressure drug Coreg.



from Biotech News